Kidney function may affect how obesity drug works

NCT ID NCT07429045

Completed Knowledge-focused Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how a single dose of the drug AMG 133 is processed by the body in people with normal kidney function compared to those with various levels of kidney problems. A total of 44 adults aged 18 to 75 who are overweight or obese took part. The goal was to understand safety and drug levels, not to treat obesity directly.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVERWEIGHT AND OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

impaired renal function disease Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVERWEIGHT AND OBESITY

Contacts and locations

Show contact details

Locations

AdvancedPharma CR LLC

Miami, Florida, 33147-4040, United States
Floridian Clinical Research, LLC

Miami Lakes, Florida, 33016, United States
Omega Research Group, LLC - Orlando

Orlando, Florida, 32806-1133, United States
Orange County Research Center

Lake Forest, California, 92630, United States
Orlando Clinical Research Center

Orlando, Florida, 32809-3017, United States